The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

A rush of vaccine-seeking customers and staff shortages are squeezing drugstores around the country.